Clene Inc (CLNN): Market Cap to Revenue Ratio
The development of nanotherapy involves immense risks and a fierce battle for leadership in sclerosis treatment for Clene Inc. (CLNN). The price-to-sales ratio helps identify asset overbought conditions in a timely manner, while the 234.60 metric serves as the baseline indicator. The unique drug CNM-Au8 provides neurons with energy; however, a critical liquidity deficit for regulatory approval requires management to urgently seek capital.
Metric breakdowns and analytics for Clene Inc. (CLNN)
- price and consensus price forecast:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- business earnings and investment ratios data:
CLNN - Net Profit|Expected Net Profit Clene Inc.|CLNN - Price to Earnings Ratio|Forward P/E Multiple clene.com|CLNN - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Clene Nanomedicine|CLNN - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Clene|CLNN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months clene.com|CLNN - Earnings per share growth in current year|Net earnings per share growth forecast for next year Clene Inc.
- sales revenue and business income indicators:
Fundamental company analysis:Clene Inc (CLNN)
Clene Inc. is investing in a highly qualified staff of physicists and neurobiologists to develop multiple sclerosis therapies. The capitalization of these R&D assets correlates with sales volume, forming the 234.60 ratio. This metric measures the market value of a single unit of revenue, allowing for an assessment of whether the business is overvalued or undervalued. The price-to-sales dynamics help investors compare the current value of the company with its historical fundamental basis.
Competitors of Clene Inc.
Price-to-Revenue Coefficient biogen.com|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|RGC: Market Cap to Revenue Ratio|Axsome Therapeutics Inc - P/S Multiple|ACADIA Corp (ACAD) - Market Cap to Revenue|XENE (Xenon Pharmaceuticals) - Market Cap to Revenue|VKTX - Price-to-Revenue Coefficient|SUPN (Supernus) - P/S Multiple|Market Cap to Revenue Catalyst Pharma (CPRX)|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|Price-to-Revenue Ratio HRMY (Harmony Corp)|Price-to-Revenue Ratio Biohaven Ltd. BHVN|AMLX: Market Cap to Revenue Ratio|TRVI - Price-to-Revenue Ratio|PRAX (Praxis Precision Medicines Inc) - Market Cap to Revenue Ratio|Anavex Corp (AVXL) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CBLL|PRTA (Prothena Biosciences) - P/S Multiple|Price to Sales Alector Therapeutics ALEC|Market Cap to Revenue ANNX (Annexon)|P/S Multiple omeros.com (OMER)|Price-to-Revenue Ratio Neurogene Corp NGNE|Market Capitalization-to-Revenue Ratio ACIU|VYGR - Price-to-Revenue Ratio|Price to Sales neumoratx.com|SCLX: P/S Multiple|Market Cap to Revenue Tevogen Bio Holdings Inc.|Price-to-Revenue Ratio Alpha Cognition Inc|Price-to-Revenue Ratio CGTX|P/S Multiple IKT|SAVA - Price to Sales|Price-to-Revenue Ratio Assertio ASRT|COYA: Market Cap to Revenue Ratio|VistaGen Therapeutics Inc - P/S Multiple|Price to Sales Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals) - Market Cap to Revenue|cervomed.com - Market Capitalization-to-Revenue Ratio|ATHE (Alterity Therapeutics Ltd.) - P/S Multiple|PepGen Corp (PEPG) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|Relmada Corp - Market Cap to Revenue Ratio|P/S Multiple ANVS (Annovis Bio, Inc.)|GRCE - Market Cap to Revenue|AIFF: Market Cap to Revenue|Price-to-Revenue Coefficient Klotho Neurosciences Inc KLTO|NRSN: P/S Multiple|Market Cap to Revenue Reviva Pharmaceuticals, Inc.|Price-to-Revenue Ratio MetaVia Inc.|Price-to-Revenue Ratio NRXS|Price-to-Revenue Ratio Helius Medical (HSDT)|passagebio.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|NERV: Market Cap to Revenue Ratio|ATHA - Price-to-Revenue Ratio|ADXN (addextherapeutics.com) - Market Cap to Revenue Ratio|ALZN: P/S Multiple|Price to Sales Cyclerion Therapeutics, Inc. (CYCN)|Market Cap to Revenue PTIX|P/S Multiple Pasithea|Price-to-Revenue Ratio Cortigent, Inc. (CRGT)|ATXI (avenuetx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio BrainStorm Cell Therapeutics BCLI|Cara Therapeutics Inc. (CARA) - Price to Sales|Chromocell Therapeutics Corporation - P/S Multiple|Eliem Therapeutics (ELYM) - Market Cap to Revenue|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|LBPH (longboardpharma.com) - Price-to-Revenue Ratio|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|Price to Sales NKGen Biotech Inc NKGN|Price-to-Revenue Ratio NeuroBo (NRBO)|Sage Therapeutics Inc - Market Cap to Revenue Ratio|P/S Multiple SNPX (Synaptogenix, Inc.)|trevena.com (TRVN) - Price to Sales|VIGL: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio WENA (anewmeds.com)|CERE: P/S Multiple
